TS-DP2 is a recombinant human granulocyte colony stimulating factor (rhG-CSF) manufactured by TS Corporation. We conducted a four-week study of TS-DP2 (test article) in repeated intravenous doses in male and female Sprague-Dawley (SD) rats. Lenograstim was used as a reference article and was administered intravenously at a dose of 1000 µg/kg/day. Rats received TS-DP2 intravenously at doses of 250, 500, and 1000 µg/kg/day once daily for 4 weeks, and evaluated following a 2-week recovery period. Edema in the hind limbs and loss of mean body weight and body weight gain were observed in both the highest dose group of TS-DP2 and the lenograstim group in male rats. Fibro-osseous lesions were observed in the lenograstim group in both sexes, and at all groups of TS-DP2 in males, and at doses of TS-DP2 500 µg/kg/ day and higher in females. The lesion was considered a toxicological change. Therefore, bone is the primary toxicological target of TS-DP2. The lowest observed adverse effect level (LOAEL) in males was 250 µg/kg/day, and no observed adverse effect level (NOAEL) in females was 250 µg/kg/day in this study. In the toxicokinetic study, the serum concentrations of G-CSF were maintained until 8 hr after administration. The systemic exposures (AUC 0 -2 4 h and C 0 ) were not markedly different between male and female rats, between the administration periods, or between TS-DP2 and lenograstim. In conclusion, TS-DP2 shows toxicological similarity to lenograstim over 4-weeks of repeated doses in rats.
INTRODUCTION
The two hematopoietic growth factors used clinically are recombinant human (rh) granulocyte colony-stimulating factor (G-CSF, filgrastim [Neupogen] ) and granulocytemacrophage colony-stimulating factor (GM-CSF, sargramostim [Leukine]). These factors differ significantly in their role in hematopoiesis and the regulation of mature effector cell function. G-CSF regulates neutrophil production and and release of neutrophils from the marrow in response to infection. It can also regulate release of neutrophils from the marrow in response to infection. Conversely, GM-CSF mediates its effects on neutrophils via phagocytic accessory cells and synergy with G-CSF, but it does not appear to have a role in basal hematopoiesis (1) .
Endogenous G-CSF levels rise during neutropenia or infection, and neutrophils are able to regulate G-CSF levels via a feedback mechanism (2) . G-CSF induces activation and priming of neutrophils in several in vitro assays via functional receptors, and increases neutrophil migration to tissues without increased adhesion to endothelial surfaces (3) . G-CSF is also an antiapoptotic factor that prolongs neutrophil survival. There are currently two "unmodified" forms of rhG-CSF worldwide in clinical use: filgrastim, which is expressed in Escherichia coli, and lenograstim, which is expressed in Chinese hamster ovary (CHO) cells and is only available outside of the United States. Following subcutaneous administration, rhG-CSF has a terminal serum half-life of approximately 2~5 hr, and confers a doserelated increase in circulating neutrophils. RhG-CSF causes increased neutrophil production, release from the marrow, 
4-Week IV Toxicity and Toxicokinetic Study of TS-DP2 in Rats 373
were housed separately in a metabolic cage for urine collection. The urinalysis (general urine examination and urine sediment test) was performed using 1 mL freshly collected urine sample, and the total volume of urine collected for 24 hr was measured. Urine was analyzed with an automatic analyzer (Clinitek Advantus, Siemens, USA) and a test strip (Multistix 10SG, SIEMENS, USA). Urinalysis parameters were glucose, pH, bilirubin, protein, ketone body, urobilinogen, occult blood, nitrite, clarity, specific gravity, and urine color. Urine sediments (white blood cell, epithelial cells, red blood cell, cast) were examined by microscope after S-M (Sternheimer-Malbin) dying.
Hematological test. Blood samples were collected from the posterior vena cava of all animals scheduled for necropsy under deep isoflurane (Ifran liquid, Hana Pharm. Co., Ltd.) anesthesia. Approximately 1 mL blood taken during the necropsy was placed into a CBC bottle (Vacutainer 3 mL, BD, USA) that contained anticoagulant EDTA-2K. Hematological parameters were determined using a Coulter counter (Advia 2120, Siemens, USA), and included the following: red blood cell (RBC), red cell distribution width (RDW), lymphocyte (LYM), hemoglobin concentration (HGB), hemoglobin distribution width (HDW), monocyte (MONO), hematocrit (HCT), platelet count (PLT), eosinophil (EOS), mean corpuscular volume (MCV), mean platelet volume (MPV), basophil (BASO), mean corpuscular hemoglobin (MCH), white blood cell (WBC), large unstained cell (LUC), mean corpuscular hemoglobin concentration (MCHC), neutrophil (NEU), and reticulocytes (RET). Blood coagulation times (activated partial thromboplastin time (APTT) and prothrombin time (PT)) were measured by the nephelometric analysis method with a coagulation time analyzer (ACL 100, Instrumentation Laboratory, USA) and reported in seconds.
Serum biochemistry.
A portion of the collected blood was placed into a 5-mL vacutainer tube (Insepack, Sekisui, Japan) that contained a clot activator. The blood was coagulated at room temperature for 15~20 min, and then centrifuged (3000 RPM, 1902 RCF, Combi-514R, Hanil, Korea) for 10 min. Serum biochemical parameters including aspartate aminotransferase (AST), total cholesterol (TCHO), creatinine (CRE), alanine aminotransferase (ALT), triglyceride (TG), inorganic phosphorus (IP), alkaline phosphatase (ALP), total protein (TP), calcium ion (Ca 2+ ), creatine phosphokinase (CPK), albumin (ALB), potassium ion (K + ), total bilirubin (TBIL), albumin/globulin ratio (A/G), sodium ion (Na + ), glucose (GLU), blood urea nitrogen (BUN), and chloride ion (Cl − ) were measured by using AU680 serum biochemistry analyzer (Beckman Coulter, USA).
Organ weights. Absolute weight and relative organ-tobody weight ratios were determined after sacrifice at 4 weeks. Tissues included brain, spleen, epididymis, pituitary gland, adrenal gland, prostate gland, lung, kidney, ovary, heart, liver, uterus, thymus, and testis.
Gross findings and histopathology. At the scheduled termination, the organs and tissues in the cranial, thoracic, and abdominal cavities of euthanized rats underwent gross examination for visible defects. Each organ was excised and fixed in 10% neutral buffered formalin, except in Davidson's fixative for the eye and in Bouin's fixative for testis and epididymis. Fixed organs were embedded in paraffin, and microsections taken at 4~5 µm thickness. Hematoxylin & eosin-stained slides were prepared, and the specimens were microscopically examined with an optical microscope. Gradation of lesions was scaled from 1 to 5 according on Pristima ® program. In general, a minimal lesion was +1 and massive lesion was +5. Two between changes in direct proportion to the evenly divided into five portions, were carried out in a semi-quantitative.
Toxicokinetics (TK) analysis.
On Day 1 and 28, blood samples of approximately 0.5 mL were collected from the jugular vein from 6 animals from each sex in the TS-DP2 group and 3 animals from each sex from the lenograstim group. The blood samples were stored at room temperature in a dark place for approximately 30 min, and then centrifuged at 3000 g (4 ο C) for approximately 20 min. The resulting serum samples were transferred to two clean labeled tubes and stored in a deep freezer (below −70 ο C) until analysis. Sample tubes were labeled with study no., period, group, animal ID, and blood collection time.
Blood collection times for TK study were pre-dose, 0.5 hr, and 24 hr after administration for G1 (negative control) and pre-dose, 5 min, 0.5 hr, 1 hr, 2 hr, 4 hr, 8 hr, and 24 hr after administration for G2-G5 (lenograstim and TS-DP2 groups), respectively. Quantification of G-CSF in rat serum was performed by the following validated method: 'Analytical method validation of G-CSF in rat serum using ELISA (Chemon Study No.: 13-RV-557)'. The analytical batch consisted of a blank, calibration samples (8 concentrations), quality control (QC) samples (low, medium, and high levels), and study samples. Calibration samples should have relative error (RE) within ± 20% LLOQ (lower limit of quantification) and ULOQ (upper limit of quantification) within ± 25%, and at least 75% of calibration samples must fulfill this criterion. QC samples should have RE within ± 20% at each level, and at least 67% of QC samples must fulfill this criterion. Sample re-analysis was performed if an analytical batch failed or obtained concentration is above the ULOQ. Incurred sample reanalysis (ISR) samples were randomly selected, and comprised 10% of the entire study samples at around C max and in the elimination phase. The variability within ± 20%, and at least 67% of ISR samples must fulfill this criterion. ISR was satisfied with acceptance criterion. Toxicokinetic analysis was performed by Phoenix TM WinNonlin ® (ver. 6.2, Pharsight) using the mean serum-concentrations at each time. Analysis model used the non-compartment model, and the area under the curve (AUC 0-24 h ) and C 0 were determined.
Statistical analysis.
The collected data for the toxicity test were statistically analyzed with the commercial program SPSS 10.1, and the significance level was set at p < 0.05. Body weight, food and water consumption, total volume of urine, hematological and clinical biochemistry tests, and organ weight were assumed to be normally distributed and analyzed by one-way ANOVA. The Student's t-test was used to test for a difference between the means of two independent groups (G1 vs. G2, G2 vs. G5). The rank transformation was performed for the urinalysis data and analyzed by the non-parametric Kruskal-Wallis' H-test.
Histopathological examination data was analyzed by the non-parametric Fisher's exact 2-tailed test using the statistical package included within Pristima. In this report, 'significant' means that it was statistically significant compared with vehicle control group unless otherwise noted.
For the TK test, the mean, standard deviation, relative error, and coefficient of variation were calculated as below equations using Microsoft ® Office Excel ® 2007.
RESULTS

Clinical signs.
No mortality was observed in any group. In the TS-DP2 groups, edema of one or both hind limbs was observed in 1~6 cases on Day 10~29 in males, and 1 or 3 cases on Day 21~30 in females, at the dose of 1000 µg/kg/ 0250 Normal 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 0500 Normal 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/ 0250 Normal 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 0500 Normal 10/10 9/10 9/10 9/10 9/10 9/10 9/10 9/10 9/10 9/10 Edema 10/10 1/10 
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day (G5), and in 1 case on Day 21~30 in females at the dose of 500 µg/kg/day (G4) ( Table 2 ). In addition, abnormal gait or ataxia was observed in 1 case on Day 10~35 in males at the dose of 1000 µg/kg/day (G5). In the lenograstim group (G2), edema of one or both hind limbs was observed in 2~7 cases on Day 22~29 in males and in 1~2 cases on Day 22~30 in females. Edema of one or both hind limbs was observed in 1~3 cases on Day 30~43 (recovery period) in males and in 1 case on Day 31~45 in females at the dose of 1000 µg/kg/day, which represents a gradual decrease over time. Ataxia was observed in 1 case (male) at the dose of 1000 µg/kg/day on Day 30~35 and then recovered. In the lenograstim group (G2), edema of one or both hind limbs was observed in 2 cases on Day 30~35 in males and in 1 case on Day 31~43 in females.
Body weight changes, food and water consumption.
The mean body weight on Days 22 and 28 and the body weight gain at the highest dose of either TS-DP2 and lenograstim in males were significantly lower than the negative control (p < 0.05 or p < 0.01) ( Fig. 1 ). During the recovery period, the mean body weight on Day 28 for TS-DP2 and on Day 28 and 35 for lenograstim in males was significantly lower than negative control (p < 0.05). Food consumption and water consumption were similar between the two groups ( Fig. 2 and 3 ). No abnormal findings or toxicologically significant differences were observed in all groups on ophthalmological examination and urinalysis (data not shown). Table 3 and 4. MCV (except females at the dose of 250 µg/ kg/day), RDW, the number and percentage of WBC and NEU, LYM, MONO, EOS (except males at the dose of 1000 µg/kg/day), BASO, and LUC of both sexes were significantly higher at all doses (p < 0.01). LUC of males at all doses were significantly increased (p < 0.05 or p < 0.01) and percentage of RET of females at the dose of 500 µg/kg/ day or less was significantly increased (p < 0.05 or p < 0.01). RBC and PLT of males at all doses were significantly decreased (p < 0.01). RBC in females at the dose of 500 µg/kg/day was significantly decreased (p < 0.05). The percentage of LYM, MONO, and EOS (except in males at the dose of 250 µg/kg/day) of both sexes was significantly decreased (p < 0.01), but it was considered to be relative changes according to the change on WBC number. Although APTT of males at the dose of 500 µg/kg/day or less was significantly decreased (p < 0.05), it was within normal ref- 0.01). The percentage of LYM, MONO, and EOS of both sexes were significantly decreased (p < 0.05 or p < 0.01), but were considered to changed relative to WBC. Comparison between lenograstim and TS-DP2 groups showed were no statistically significant changes in the main group. Conversely, at a dose of TS-DP2 1000 µg/kg/day, the WBC and LYM of males were significantly increased (p < 0.05) and APTT of females was shorter than that of lenograstim (p < 0.05) in the recovery group.
Hematological test. Statistical significance compared to negative control (G1) in hematological test is shown in
Serum biochemistry test. The statistical significance comparing negative control (G1) in clinical biological chemistry test is shown in Table 5 and 6. ALP in both sexes at all doses was significantly increased (p < 0.01). Cl − and AST (contained females at the dose of 1000 µg/kg/day) of males at all doses was significantly increased (p < 0.05 or p < 0.01). TCHO and K + were significantly decreased (p < 0.05 or p < 0.01) in males, but these values were within the normal reference range provided by Chemon. ALP in both Data are expressed as Mean ± SD (n = 10). Statistically significant from G1 (*p < 0.05; **p < 0.01) or G2 ( # p < 0.05; ## p < 0.01). G1: Negative control, G2: Reference control, G3-G5: Test article treatment groups. ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CPK: creatinine phosphokinase; TBIL, total bilirubin; GLU, glucose; TCHO, total cholesterol; TG, triglyceride; TP, total protein; ALB, albumin; A/G ratio, albumin/globulin ratio; BUN, blood urea nitrogen; CRE, creatinine; IP, inorganic phosphorus; Ca 2+ , calcium ion; Na + , sodium ion; K + , potassium ion; Cl sexes at the dose of lenograstim 1000 mg/kg was significantly increased (p < 0.01). AST in both sexes, Na + and Cl − of males, and CRE of females were significantly increased (p < 0.01). K + in both sexes, TP of males, and CPK of females were significantly decreased (p < 0.05 or p < 0.01), but these values were also within the normal reference range provided by Chemon. At a dose of TS-DP2 1000 µg/kg/day, ALP in males was significantly increased (p < 0.05) and CRE in females was significantly decreased (p < 0.01) compared to the lenograstim group. In the recovery group, AST, TBIL, ALB, and A/G ratio at the dose of 1000 µg/kg/day of males and Cl − of females were significantly increased (p < 0.05 or p < 0.01). GLU of males and Ca 2+ of females were significantly decreased (p < 0.05 or p < 0.01). There was no statistical significance between the lenograstim and TS-DP2 groups.
Organ weights. Absolute and relative weights are shown in Table 7 , 8, 9, and 10 . At all doses, the absolute and The body weights were measured right before necropsy after overnight fasting. Data are expressed as Mean ± SD (n = 10). Statistically significant from G1 (*p < 0.05; **p < 0.01) or G2 ( # p < 0.05; ## p < 0.01). G1: Negative control, G2: Reference control, G3-G5: Test article treatment groups. relative weights of the spleen in both sexes were significantly higher than negative control (G1) (p < 0.01). At the dose of 1000 µg/kg/day, the absolute weight of heart of males was also significantly lower (p < 0.05) and lung of females was significantly higher (p < 0.01). In males, the absolute weight of both kidneys at all doses and the relative weight of left kidney at doses of 250 and 500 µg/kg/day were significantly decreased (p < 0.05 or p < 0.01). In addition, at all doses, the relative weight of lung was significantly higher in males (p < 0.05 or p < 0.01) and the absolute weight of thymus was significantly decreased (p < 0.05). In the lenograstim group, lower fasting body weight was considered to be a source of the observed changes. Fasting body weight of males was significantly lower (p < 0.05) and the absolute and relative weights of liver of females were significantly increased (p < 0.05). The absolute and relative weights of spleen and lung of both sexes were significantly increased (p < 0.05 or p < 0.01).
In addition, the relative weight of the left testis and both epididymidis was significantly increased (p < 0.05), and the relative weight of both kidneys and the absolute and rela-tive weights of thymus of males were significantly decreased (p < 0.05 or p < 0.01). Decreased fasting body weight was again considered to be a source of the observed changes. At the dose of 1000 µg/kg/day of TS-DP2, the absolute and relative weights of the left adrenal gland and the relative weight of hearts in males were significantly decreased compared to the lenograstim group (p < 0.05 or p < 0.01). There was no statistically significant change in the recovery group.
Necropsy findings. Main necropsy findings are shown in Table 11 . The increased size of the spleen was observed at all doses in males and in 3, 3, and 9 cases in females at doses of 250, 500, and 1000 µg/kg/day, respectively. Hind limb edema was observed in 2 cases in males and 1 case in females at the dose of TS-DP2 1000 µg/kg/day. In the lenograstim group, the increased size of spleen was observed in all cases in males and in 8 cases in females, and hind limb edema was observed in 3 cases in males. In the recovery groups, the increased size of spleen was seen in 2 cases and the hind limb edema in 1 case of males at the dose of 1000 µg/kg/day of TS-DP2. There were no changes Table 10 . Absolute (g) and relative organ (%) weights intravenously treated with TS-DP2 for 4 weeks in female rats (recovery groups) in recovery group of TS-DP2. There were no any other toxicologically meaningful changes in either group in the necropsy findings.
Histopathological examinations. The important lesions
were the signs observed on liver, spleen, femur, sternum, hind limb, and tartus (Table 12 and 13) ( Fig. 4, 5 and 6 ). In the main groups, the important lesion observed on the liver was infiltration of mononuclear cell and the increase of erythroid and myeloid extramedullary hematopoiesis, occurring in a dose-dependent manner. The erythroid and myeloid extramedullary hematopoiesis were significantly higher at all TS-DP2 doses and lenograstim for both sexes compared to negative control (p < 0.05 or p < 0.01 or p < 0.001). The main lesion observed on spleen was due to the increase of erythroid and myeloid extramedullary hematopoiesis. These lesions were significantly higher at all TS-DP2 doses and the lenograstim groups in both sexes (p < 0.05 or p < 0.01 Table 11 . Necropsy findings intravenously treated with TS-DP2 for 4 weeks in rats Findings  G1  G2  G3  G4  G5  G1  G2  G5   Number examined  10  10  10  10 Findings  G1  G2  G3  G4  G5  G1  G2  G5   Number examined  10  10  10  10 In animals with severe hind limb edema observed on necropsy, myeloid hematopoiesis was observed in 2 and 1 case, 
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DP2, any abnormal lesion was not detected.
In the recovery group, myeloid extramedullary hematopoiesis and infiltration of mononuclear cell were significantly increased at a dose of 1000 µg/kg/day in males (p < 0.05). The myeloid hematopoiesis observed in bone marrow was significantly higher in the lenograstim group males (p < 0.01). The fibro-osseous lesion observed on the femorotibial joint was observed in 1 case at the TS-DP2 dose of vances between the lenograstim group and the TS-DP2 1000 µg/kg/day group, in both degree and occurrence of lesions.
Toxicokinetics study. The toxicokinetic parameters of G-CSF are displayed in Table 14 . The serum concentrations are displayed in Table 15 and 16, and graphically in Fig. 7 and 8 . The negative control (G0) (Water for injection), positive reference article (G2) (Choongwae Neutrogin Injection: 1000 µg/kg/day), and test article (TS-DP2: 250 [G3], 500 [G4], and 1000 [G5] µg/kg/day) were intravenously administered to male and female rats for 4 weeks.
On administration initiation day (Day 1), the G-CSF in rat serum remained at a concentration above LLOQ (0.2 ng/ mL) until 8 hr after administration in G3 (250 µg/kg/day) and G4 (500 µg/kg/day). In some animals in the G2 (1000 µg/kg/day) and G5 (1000 µg/kg/day) groups, the concentration was above the LLOQ until the last blood sampling time (24 hr). Overall, G-CSF in rat serum persisted until at least 8 hr after administration. On Day 28, the G-CSF in rat serum was measured at above the LLOQ at prior administration, and until the last blood sampling time in some animals. Overall, the G-CSF in rat serum was maintained until 8 hr after administration on Day 1 and Day 28. G-CSF was not detected in the negative control group.
On Day 1, the ratios of male to female of AUC 0-24 h and C 0 values were 1.1-and 1.0-fold (G2), 1.2-and 1.0-fold (G3), 1.1-and 1.0-fold (G4), and 1.1-and 1.0-fold (G5), and on Day 28, 1.7-and 1.2-fold (G2), 1.5-and 0.9-fold (G3), 1.5-and 1.2-fold (G4), and 1.1-and 1.1-fold (G5), respectively. The systemic exposure (AUC 0-24 h and C 0 ) was not markedly different (> 2-fold or < 0.5-fold) between male and female rats.
When the doses were gradually increased 2.0-fold, the grand means of AUC 0-24 h values were increased 2.5-and 2.0-fold (Day 1) or 1.8-and 1.9-fold (Day 28), and the grand means of C 0 values were increased 2.5-and 1.9-fold (Day 1) or 1.8-and 1.5-fold (Day 28). Overall, the systemic exposure (AUC 0-24 h and C 0 ) increased in a doserelated manner.
The ratios of Day 28 to Day 1 of grand mean AUC 0-24 h and C 0 values were 1.2-and 1.3-fold (G2), 1.5-and 1.7-fold (G3), 1.1-and 1.2-fold (G4), and 1.0-and 0.9-fold (G5), respectively. Therefore the systemic exposure (AUC 0-24 h and C 0 ) was not markedly different (> 2-fold or < 0.5-fold) in the administration period. The ratios of grand mean AUC 0-24 h and C 0 values of TS-DP2 to lenograstim were 0.9-and 0.9-fold (Day 1) and 0.8and 0.6-fold (Day 28) at the same dose (1000 µg/kg/day), respectively. Therefore, the systemic exposure of TS-DP2 was similar to that of lenograstim.
In conclusion, systemic exposure of G-CSFs tested was not markedly different between males and females, and exhibited non-linear kinetics and accumulation at all dose levels. Therefore, the toxicokinetic profile of TS-DP2 is similar to that of lenograstim.
DISCUSSION
We conducted toxicity and toxicokinetic studies in SD rats to compare TS-DP2, a new rhG-CSF, and lenograstim, a reference rhG-CSF. The toxicity test was conducted over 4 weeks using IV injection and allowing for a 2-week recovery period. The toxicokinetic test was done separately from the toxicity test. Most of the results in these studies were similar to previous reports for G-CSF products.
In a 4-week repeated dose intravenous toxicity study, there was no significant difference between TS-DP2 and lenograstim in the subjects' water consumption, ophthalmological examination, and urinalysis. Clinically, hind limb edema, abnormal gait, and ataxia were observed in the TS-DP2 1000 µg/kg/day group, and hind limb edema was observed in the lenograstim 1000 µg/kg/day group. These observations were considered effects of the G-CSF, and were improved in the recovery period. A decrease in mean body weight or body weight gain was observed in male main and recovery groups receiving lenograstim, as well as dose of 1000 µg/kg/day. There were no significant differences between the TS-DP2 group and the lenograstim group. RBC decreased in both sexes in the lenograstim group and male main groups at all doses, and in females in the TS-DP2 group. Increase in RDW was considered dosedependent, and changes in erythroid extramedullary hematopoiesis in the spleen and liver were observed. These changes seemed to be related to treatment with G-CSF, but were considered not to be indicative of toxicology, as the numerical values measured were within range or only slightly elevated compared to the normal reference range provided by Chemon Inc. Significant increases in WBC observed in both sexes at all TS-DP2 doses and in the 
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lenograstim group were considered to be related to an increase in neutrophils (11) , myeloid extramedullary hematopoiesis in spleen and liver, and myeloid hematopoiesis on bone marrow. This observation is expected, considering the pharmacological action of a G-CSF medication. The changes were within the normal reference range of SD rats in the recovery groups, so they were considered non-toxicological changes. The significant decrease of PLT observed in males at all doses of TS-DP2 and in both sexes in the lenograstim group was attributed to the G-CSF, and similar to the increased MPV and the decreased in PLT on females. In a previous study, PLT were decreased after lenograstim administration (12) . These changes were considered nontoxicological changes.
In a clinical biochemistry test, the significant increase of ALP observed in both sexes in the lenograstim group and at all doses of TS-DP2 was considered to be related to the G-CSF. It was also related to the formation of fibro-osseous lesion on the femorotibial joint and tartus. This was related with the increase in neutrophil count, as ALP was a component within the neutrophil (13, 14) . ALP was likewise increased after lenograstim administration (14) , which was attributed to pharmacological activity by G-CSF. The changes in clinical biochemistry items observed at the reference control and test article recovery groups were considered to be unrelated to the respective medications, because they were not observed in the main groups or observed only in a single sex, were within normal reference range for SD rats, or the variance was small.
The significant increase of absolute and relative of spleen organ weight was observed dose-dependently in both sexes at all doses of TS-DP2 and the lenograstim group was considered to be related to the pharmacological effect of G-CSF. It was also related to the increased size of the spleen in necropsy findings, and the increase of erythroid and myeloid extramedullary hematopoiesis in the spleen seen on histopathological examination. This was considered to undergo delayed recovery, but did not cause abnormal lesions on histopathological examination. Therefore, they were considered non-toxicological changes. The significant decrease in fasting body weight in the main and recovery groups of lenograstim in males was considered to be related to the drug, which showed a significant suppression of weight gain (approximately 10%). Other changes were considered spontaneous, because they were not observed on hematological tests, clinical biochemistry tests, or necropsy findings.
In necropsy finding, the hind limb edema in both sexes in the lenograstim group and at all doses in the TS-DP2 group was attributed to the pharmacological activity of G-CSF. It was also related to the myeloid hematopoiesis and fibroosseous lesions observed on the hind limb (contained tartus) upon histopathological examination.
The lesions observed on histopathological examination on the spleen, femur, sternum, and hind limb (contained tar-tus) exhibited a dose-dependent relationship. The lesions were considered to be related to the G-CSF given, and were observed on hematological and clinical biochemistry tests. Among them, the myeloid extramedullary hematopoiesis on liver and spleen-related myeloid hematopoiesis on bone marrow was considered a pharmacological action of the G-CSF. The fibro-osseous lesion on the femorotibial joint characterized by increased appearance of osteoclasts and fibroblasts, and osteoanagenesis was observed in a part of femorotibial joint. The increased number of osteoclasts was attributed to the pharmacological activity of TS-DP2 and lenograstim. It was observed in both sexes in the lenograstim group, at all TS-DP2 doses in males, and at the TS-DP2 dose of 500 µg/kg/day or more in females. They were observed changes related to the lesions on histopathology examination, similar to hind limb edema and ataxia. Fibroosseous lesions were considered to be toxicological changes, and were observed in both sexes in the lenograstim group, at all TS-DP2 doses in males, and at the TS-DP2 dose of 500 µg/kg/day or more in females. Osteolysis or osteogenesis were expected, as well as weakening of the bone and the subsequent effects on surrounding tissues, including as blood vessels, nerves, and bone marrow. The infiltration of mononuclear cells in the liver and the increase of erythroid extramedullary hematopoiesis in the spleen and liver were observed in both sexes in the lenograstim group and at all doses of TS-DP2. This infiltration effect was attributed to the pharmacological activity of a G-CSF, because related changes were observed on hematological tests. It was considered to be a non-toxicological change, because the data were within the reference range or only slightly over and improved in the recovery group. Other lesions that have previously been shown to occur spontaneously in SD rats were considered to be unrelated to the test article (9, 10, (15) (16) (17) (18) (19) .
In a 4-week repeated IV dose study of TS-DP2 in SD rats, including a 2-week recovery period, there were several histological, biochemical, and physiological changes attributed to the G-CSF. Clinical hind limb edema, the decrease of mean and gain in body weight in males in the lenograstim and high-dose TS-DP2 group, the decrease of RBC and PLT, the increase of items related to WBC on hematological tests, the increase of ALP on biochemistry tests, the increase of the absolute and relative weights of spleen, and the lesions on liver, spleen, femur, sternum, hind limb, and tartus on histopathological examination were considered to be related to the reference control and test article. Above all, the fibro-osseous lesion observed on both sexes in the lenograstim group, at all TS-DP2 doses in males, and at TS-DP2 dose of 500 µg/kg/day or more in females was considered to be a toxicological change.
In conclusion, the toxicological target of TS-DP2 is primarily bone, with a lowest observed adverse effect level (LOAEL) in males set at 250 µg/kg/day, and no observed adverse effect level (NOAEL) in females at 250 µg/kg/day in this study.
The TS-DP2 dose of 1000 µg/kg/day has shown similar effects to lenograstim at a dose of 1000 µg/kg/day in this study under these experimental conditions. In the toxicokinetic study, the ratios (lenograstim versus TS-DP2) of grand mean AUC 0-24 h and C 0 values were 0.9-and 0.9-fold (Day 1) and 0.8-and 0.6-fold (Day 28) at the same dose level (1000 µg/kg/day). The systemic exposure of TS-DP2 was similar to lenograstim. Therefore, the systemic exposure of the two G-CSF products was similar in males and females, showed non-linear kinetics, and was able to accumulate in all dose levels. The systemic exposure of TS-DP2 was similar to lenograstim at the same dose.
Most of the results were attributed to the pharmacological action of rhG-CSF. Although there were some differences observed in the toxicity tests, they were not thought to represent a significant discrepancy between TS-DP2 and lenograstim. Consequently, the test article TS-DP2 was shown to be biologically similar to lenograstim in rats.
